Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 versus LINCOMYCIN HYDROCHLORIDE.
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
600-900 mg IV every 8 hours, or 900 mg IV every 12 hours.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
Terminal elimination half-life is 2.4–3.0 hours in adults with normal hepatic and renal function; prolonged in severe hepatic impairment (up to 8–10 hours) and in neonates (8–20 hours).
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Approximately 10% of administered dose excreted renally as active drug; significant biliary/fecal elimination (about 40% as active drug and metabolites) via enterohepatic circulation.
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic